1. Home /
  2. Stock of the Day

Stock of the Day

Could Small Drug Trial Hold Big Potential for Amgen?

Could Small Drug Trial Hold Big Potential for Amgen?

The results of a lung-cancer drug got me to go long on the stock, but the larger picture is complicated.

Apple Watch Begins: What Jim Cramer Is Watching In the Markets

Apple Watch Begins: What Jim Cramer Is Watching In the Markets

Jim Cramer and Action Alerts PLUS research analyst Zev Fima broke down everything you need to navigate your Monday.

Amgen's Lower Open Tests Support but the Bigger Picture Is More Important

Amgen's Lower Open Tests Support but the Bigger Picture Is More Important

Let's check out the charts to get a sense of where prices could be headed.

Can the Market Rise 'By Innovation Only?' Jim Cramer on Apple and China

Can the Market Rise 'By Innovation Only?' Jim Cramer on Apple and China

Jim Cramer and Action Alerts PLUS research analyst Zev Fima break down everything you need to kickstart your week from Apple to China.

Jim Cramer Breaks Down Lululemon's Earnings Beat

Jim Cramer Breaks Down Lululemon's Earnings Beat

Jim explains why Lululemon is a buy even at all-time highs.

Lululemon: Just Buy the Darned Stock, Don't Trade It

Lululemon: Just Buy the Darned Stock, Don't Trade It

This company has navigated the trade war perhaps better than any other retailer.

Jim Cramer Breaks Down Nonfarm Payrolls, the Fed and Lululemon's Earnings

Jim Cramer Breaks Down Nonfarm Payrolls, the Fed and Lululemon's Earnings

Jim Cramer breaks down what investors need to know about the nonfarm payrolls report, the Fed, China and Lululemon's earnings.

Lululemon Truly Is a Best-in-Class Retail Name

Lululemon Truly Is a Best-in-Class Retail Name

It appears the growth in the men's category may not be a flash in the pan.

Lululemon Reaches a Key Price Target: What Should Investors Do Now?

Lululemon Reaches a Key Price Target: What Should Investors Do Now?

LULU is trading around above $200 after blowout earnings.

Lululemon Leaps as 5-Year Growth Plan Picks Up Pace

Lululemon Leaps as 5-Year Growth Plan Picks Up Pace

Lululemon's earnings results are leading to even more gains for shareholders already rewarded handsomely in 2019.